Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consumers need sun care education

This article was originally published in The Tan Sheet

Executive Summary

Participants in the Suncare 2020 Symposium in New York agree sun care product leaders must collaborate to educate the public because many consumers still do not understand effective use of sunscreen, Merck Consumer Care division announces. Themes that emerged at the meeting include the need to create information to change consumer behavior in regard to tanning and sun protection, and the need to educate the public to navigate expected sunscreen labeling and product performance rules, in the FDA's final sunscreen monograph expected this fall (1"The Tan Sheet" April 27, 2010). The Coppertone Solar Research Center, which hosted the symposium, plans to offer a guide to help consumers understand anticipated changes, including a UVA protection rating on sunscreen labels that likely will be required, limitations to anti-aging claims, new active ingredients and an expected cap on SPF

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts